MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'evista'. Sat, 03 Sep 2011 02:38:12 +0100 http://www.medworm.com/index.php?rid=4715022&cid=t_133936_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FfKoTWEYTHfw%2F The latest monthly tally for prescription meds shows that prices rose again last month, compared with a year ago. Specifically, there were 14 price increases, up an average 6.7 percent, versus price hikes on 10 drugs in March 2010 that averaged 6.5 percent, according to Barclays Capital analyst Lawrence Marsh, who reviewed data from First DataBank on the top 130 brand-name prescription drugs. Going back in time, there were 19 price increases in March 2009, but the average price hike was 6.0 percent. In March 2008, prices rose on just eight meds at an average increase of 9 percent, while in March 2007, there were price increases on seven drugs at an average of 4.9 percent. And in March 2006, drugmakers boosted prices on seven meds at an average 5.8 percent. Last month, Marsh found price hi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4715022 Thu, 14 Apr 2011 13:43:49 +0100 4715022 http://www.medworm.com/index.php?rid=3929458&cid=t_133936_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F3Eqe6D-7b1U%2F Top of the morning to you. A sparkly day is unfolding here on the Pharmalot corporate campus, where we are following various leads and trying to make sense of this big old world. To help the process, we are brewing our mandatory cup of stimulation. Please join us as you prepare to climb your own mountains. Meanwhile, have a great day and stay in touch… FDA Warns Of Increased Death With Pfizer Antibiotic (Dow Jones) Merck Cancer Drug Used In AIDS Trials (Bloomberg News) Europe Approves AstraZeneca’s Seroquel XR (PharmaTimes) Boehringer Ingelheim Opens Facility In China (Outsourcing Pharma) Appeals Court Upholds Lilly’s Evista Patents (Indianapolis Business Journal) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3929458 Thu, 02 Sep 2010 11:44:03 +0100 3929458 http://www.medworm.com/index.php?rid=2006401&cid=t_133936_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F471219058%2F And so the long holiday weekend here in the states has ended. We hope you had a nice time, whatever you did. Certainly, a respite was in order. Now, though, the time has come to return to the routine, which means meetings, projects and deadlines are looming. To help you along, we have gathered a few interesting items. So grab that cup of stimulation and dig in… Lower-Cost Drugs Forecast Under Obama Administration (Chicago Tribune) Will Teva Conduct At-Risk Launch Of Lilly’s Evista? (Bloomberg News) FDA Frets Over Pig Virus In Solvay Enzyme (Reuters) Some US Docs May Forego Vaccines Over Cost (Associated Press) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2006401 Mon, 01 Dec 2008 11:40:47 +0100 2006401 http://www.medworm.com/index.php?rid=1790484&cid=t_133936_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F390987933%2F Next Tuesday, the struggling biotech releases data about denosumab, an experimental osteoporosis drug, and the data could make the difference between a multi-billion-dollar med and an also-ran in a crowded field. No small moment for a company that has staggered from setback to setback with its existing meds. “Denosumab is a mega-blockbuster opportunity and will now emerge as the principal long-term value driver,” Morgan Stanley analyst Steven Harr wrote in a recent research note, Reuters reports. “We see a high probability of regulatory success given data to date.” Two months ago, Amgen reported denosumab significantly reduced the risk of spine fracture in a three-year trial of 7,800 post-menopausal women, but never disclosed exactly how much the risk was reduced. T... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1790484 Fri, 12 Sep 2008 21:02:46 +0100 1790484 http://www.medworm.com/index.php?rid=1488221&cid=t_133936_150_f&fid=34889&url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2008%2F06%2Fevista-nobody-is-pointing-gun-at-us.html According to an IndyStar.com article, the new Evista ads "are raising a new round of criticism from some women's health groups" (see "A new pitch for an old pill"). Lilly markets Evista.The issue is whether or not Evista's breast cancer prevention benefit is worth the risk."Evista," says the article, "has been shown to raise the risk of blood clots and fatal strokes. In one clinical trial of 10,000 patients with coronary problems and other health issues, women who took Evista had a 49 percent higher risk of dying if they suffered a stroke than those who took a placebo."The drug's packaging insert even carries a black-box warning about those risks -- the strongest warning required by the Food and Drug Administration."The article seems to be a "fair and balanced" critique and quotes a few di... Pharma Marketing Blog blogs http://www.medworm.com/rss/comments.php?id=1488221 Mon, 02 Jun 2008 18:03:00 +0100 1488221 http://www.medworm.com/index.php?rid=1208099&cid=t_133936_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F229622411%2F The drugmaker has been trying to stop a UK pharmacy, which is buying Lilly drugs in Turkey, from selling them to Internet pharmacies in Canada. But London’s High Court threw out the case, Reuters reports. The move is a big setback Lilly, which hoped to plug a cut-price route for med reaching the US. But faced with some of the highest drug prices in the world, many US patients have resorted to Canadian Internet pharmacies, which can offer discounts of as much as 80 percent by buying drugs for a lower price from other countries. The trademarks at the center of the case were the Lilly name, as well as the drug names Cialis, Evista, Humulin and Humalog. Evista is a drug for osteoporosis and Humalog and Humulin are for diabetes. And Cialis is for impotence. In November, Lilly won a tempor... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1208099 Tue, 05 Feb 2008 14:29:51 +0100 1208099 http://www.medworm.com/index.php?rid=1101718&cid=t_133936_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F202218516%2F Scott Gottlieb likes to kick up dust. A former FDA deputy commish, who is a trained physician, resident fellow at the American Enterprise Institute and consultant to Novartis, wrote an Op-Ed in The Wall Street Journal yesterday in which he skewered the federal government for branding off-label promotion a speech “crime.” In his view, such activities may really be a public service. In presenting his argument, he cites a case two years ago in which Lilly pled guilty to a criminal indictment and paid $36 million in fines for promoting studies that its Evista cancer drug could prevent breast cancer in post-menopausal women. Back then, Evista was approved only for treating osteoporosis, not preventing cancer, he noted. But three months ago, the FDA approved the drug for use against ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1101718 Tue, 18 Dec 2007 14:42:53 +0100 1101718 http://www.medworm.com/index.php?rid=925341&cid=t_133936_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F164772674%2Ffda_approves_evista_raloxifene_1.html The FDA has approved Raloxifene as a treatment to reduce breast cancer risk in menopausal women. Raloxifene, under the brand name Evista, has previously been approved for postmenopausal women with osteoporosis but is now available to women with high risk for invasive breast cancer. Based on clinical studies of postmenopausal women over a 10 year period of time, raloxifene "provides an important new option for women at heightened risk of breast cancer," said Dr. Steven Galson, director of the FDA's Center for Drug Evaluation and Research. (Source: PharmaGazette) PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=925341 Wed, 03 Oct 2007 17:30:40 +0100 925341 http://www.medworm.com/index.php?rid=2510405&cid=t_133936_87_f&fid=34865&url=http%3A%2F%2Fwww.thecancerblog.com%2F2007%2F09%2F14%2Feli-lillys-evista-cancer-drug-approved-by-fda%2F Filed under: Drug, All CancersIt's interesting when a drug is re-purposed into something aimed at fighting cancer, but that is what has happened to Evista, a prescription drug made by Eli Lilly which was originally for osteoporosis patients.The FDA has officially approved Evista for use in breast cancer patients as of late this week, although the drug will now come with a box warning advising patients of a heightened risk for stroke by taking the drug.I'm not sure -- are some drugs worth the possible benefits when certain side effects can be just as bad as what is trying to be treated?Read | Permalink | Email this | Linking Blogs | Comments (Source: The Cancer Blog) The Cancer Blog blogs http://www.medworm.com/rss/comments.php?id=2510405 Thu, 13 Sep 2007 23:00:00 +0100 2510405 http://www.medworm.com/index.php?rid=763187&cid=t_133936_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F138111770%2F Two days ago, we pointed out a Lilly press release about an FDA panel endorsing its Evista osteoporosis med for two extra uses - reducing the chance of breast cancer in post-menopausal women with osteoporosis, or for those at high risk for the disease. But Lilly’s press release contained this sub-hed: “Evista is currently indicated for the prevention and treatment of osteoporosis and may provide (emphasis added) an important option for postmenopausal women at increased risk for breast cancer.” The FDA, however, hasn’t approved that indication yet. In fact, Lilly paid a $36 million fine in 2005 for illegally promoting Evista to docs as a breast cancer “preventative,” and signed a consent decree, which says: Lilly is “permanently enjoined from directly or indirectly promoting E... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=763187 Fri, 27 Jul 2007 23:07:57 +0100 763187 http://www.medworm.com/index.php?rid=760654&cid=t_133936_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F137756966%2F Yesterday, we pointed out a Lilly press release about an FDA panel endorsing its Evista osteoporosis med for two extra uses - reducing the risk of invasive breast cancer in post-menopausal women with osteoporosis, and also for lowering the chance of getting breast cancer in post-menopausal women at high risk for the disease. But Lilly’s press release contained this sub-hed: “Evista is currently indicated for the prevention and treatment of osteoporosis and may provide (emphasis added) an important option for postmenopausal women at increased risk for breast cancer.” The FDA, however, hasn’t approved that indication yet. In fact, Lilly paid a $36 million fine in 2005 for illegally promoting Evista to docs as a breast cancer “preventative,” and signed a consent decree, which ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=760654 Thu, 26 Jul 2007 23:00:10 +0100 760654 http://www.medworm.com/index.php?rid=758087&cid=t_133936_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F137256805%2F Yesterday, we noted how an FDA advisory committee recommended the drugmaker’s osteoporosis med for reducing the risk of invasive breast cancer in post-menopausal women with osteoporosis, and also endorsed the drug for lowering the chance of getting breast cancer in post-menopausal women at high risk for the disease. Curiously, Lilly’s press release contained an interesting sub-hed: “Evista is currently indicated for the prevention and treatment of osteoporosis and may provide (emphasis added) an important option for postmenopausal women at increased risk for breast cancer.” Why did we highlight the latter part of the statement? The FDA hasn’t actually approved that indication yet. As pointed out by Breast Cancer Action, an advocacy group that opposes FDA appro... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=758087 Wed, 25 Jul 2007 15:01:26 +0100 758087 http://www.medworm.com/index.php?rid=755761&cid=t_133936_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F136997327%2F An FDA advisory committee this afternoon voted 8 to 6 to endorse Evista’s approval for reducing the risk of invasive breast cancer in post-menopausal women with osteoporosis, and also voted 10 to 4 to recommend the med for lowering the chance of getting breast cancer in post-menopausal women at high risk for the disease. The FDA will make a final decision but usually follows panel recommendations; Lilly says the FDA was expected to rule in September. The drugmaker currently sells Evista treating and preventing osteoporosis, but wants approval to promote the med to prevent breast cancer. Panel member Dr. Antonio Grillo-Lopez, a retired oncologist, said Evista “shows at least similar efficacy and perhaps a better safety profile” than tamoxifen, the only medicine now approve... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=755761 Tue, 24 Jul 2007 21:06:48 +0100 755761